ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3
Completed
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Interventions
- Biological: Ravulizumab
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02949128
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Biological: RavulizumabBiological: Eculizumab
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT02946463
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Screening for Lysosomal Acid Lipase Deficiency
Terminated
- Conditions
- Lysosomal Acid Lipase Deficiency
- Interventions
- Other: There is no intervention in the study
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02926872
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02797821
- Locations
- 🇩🇪
University of Würzburg, Würzburg, Germany
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Vanderbilt Medical Center Endocrinology, Nashville, Tennessee, United States
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
Completed
- Conditions
- Wilson Disease
- Interventions
- Drug: Standard of Care Medications
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02763215
- Locations
- 🇬🇧
Clinical Trial Site, Guildford, United Kingdom
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Phase 1
Terminated
- Conditions
- Mucopolysaccharidosis III, Type B (MPS IIIB)Sanfilippo B
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02618512
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
Terminated
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Other: Eculizumab
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02614898
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Completed
- Conditions
- PNHParoxysmal Nocturnal Hemoglobinuria
- Interventions
- Biological: Ravulizumab
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02605993
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1
Completed
- Conditions
- PNH
- Interventions
- Biological: ALXN1210
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02598583
- Locations
- 🇰🇷
Clinical Trial Site, Ulsan, Korea, Republic of
Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
Phase 4
Completed
- Conditions
- Hypophosphatasia
- Interventions
- Biological: Asfotase Alfa
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02531867
© Copyright 2025. All Rights Reserved by MedPath